Genomics of Brain Metastases
Demographics (2)
- Diagnosis Age - Age of Diagnosis of Primary Tumor (phv00253456.v1.p1)
- Gender - Participant's gender as Male or Female (phv00253453.v1.p1)
Substance Use (1)
- Smoking - Smoking history (phv00253463.v1.p1)
Other (21)
- ANALYTE_Type - Molecular analyte (phv00253470.v1.p1)
- BM-PFS - Brain Metastasis Progression-Free Survival (years): Time elapsed from time of primary diagnosis to diagnosis of sequenced brain metastasis (phv00253461.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00253448.v1.p1)
- HER2-met - Clinical HER2 status of metastasis (if breast cancer) (phv00253459.v1.p1)
- HER2-primary - Clinical HER2 status of primary (if breast cancer) (phv00253458.v1.p1)
- HER2-prior - Anti-HER2 treatment prior to brain metastasis (if breast cancer) (phv00253457.v1.p1)
- Histology group - Histology of Primary Tumor (phv00253455.v1.p1)
- Other-Brain - Other brain metastases (phv00253464.v1.p1)
- Other-Sites - Other metastatic sites (phv00253465.v1.p1)
- Primary Site - Primary site of patient tumor (phv00253454.v1.p1)
- Radiation-prior - Radiation prior to diagnosis of brain metastasis (phv00253462.v1.p1)
- SAMPID - De-identified Sample ID (phv00253467.v1.p1)
- SAMPID - Sample ID (phv00253450.v1.p1)
- Sample Type - Indicates the Tumor / Normal status of a sample (phv00253468.v1.p1)
- SAMPLE_USE - Sample Use (phv00253451.v1.p1)
- SUBJID - Unique Participant Identifier (phv00253452.v1.p1)
- SUBJID - Subject ID (phv00253449.v1.p1)
- SUBJID - Subject ID (phv00253447.v1.p1)
- Treatments - Number of systemic treatment regimens prior to brain metastasis (phv00253466.v1.p1)
- Triple-Neq - Triple-negative primary (if breast cancer) (phv00253460.v1.p1)
- Tumor Type - Indicates primary or recurrent tumor (phv00253469.v1.p1)